AMLX | Ticker Profile - Titan Protect

AMLX

Amylyx Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic · NMS

$13.32

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.6B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-11.11

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-63.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$21.50

+61% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 10 analysts covering this stock

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

https://amylyx.com

Country: United States Employees: 136 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

1.810

Excellent risk-adjusted returns

Kelly Fraction

0.1180

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

3.379

Returns exceed worst-case losses — strong risk profile

Annual Return

193.7%

Historical annualised return based on price data

Max Drawdown

-57.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-0.10

Very low correlation to market moves

52W High

$18.61

28% below the year high

52W Low

$4.71

183% above the year low

Avg Volume

1,107,493

Average daily shares traded — higher means easier to buy and sell

Short Ratio

13.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

16.9%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.48

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

2.06

Heavy leverage — higher financial risk if revenues decline

Current Ratio

17.85

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

17.53

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-71,515,872

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-150,112,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$34.00

Target Median

$21.50

Target Low

$19.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go